Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...
Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...
"attachment_1199023" align="aligncenter" width="1456"] An elderly couple receiving insulin from a pharmacist, representing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback